Certara, Inc. (CERT) Bundle
Understanding Certara, Inc. (CERT) Revenue Streams
Understanding Certara, Inc.’s Revenue Streams
Revenue Overview: For the nine months ended September 30, 2024, total revenues reached $284.8 million, an increase of 7% compared to $266.3 million in the same period of 2023.
Breakdown of Primary Revenue Sources
- Software Revenues: Increased to $113.4 million for the nine months ended September 30, 2024, up 16% from $98.1 million in 2023.
- Services Revenues: Grew to $171.4 million, a 2% increase from $168.3 million in 2023.
Year-over-Year Revenue Growth Rate
Total revenues increased by $18.5 million or 7% for the nine months ended September 30, 2024. This growth was primarily driven by strong demand for software products and technology-enabled services.
| Period | Total Revenues | Growth Rate |
|---|---|---|
| 2024 (9 months) | $284.8 million | 7% |
| 2023 (9 months) | $266.3 million | - |
Contribution of Different Business Segments to Overall Revenue
The contribution of software and services to total revenues for the nine months ended September 30, 2024 is detailed below:
- Software: 40% of total revenue
- Services: 60% of total revenue
Analysis of Significant Changes in Revenue Streams
For the three months ended September 30, 2024, total revenues were $94.8 million, an increase of 11% from $85.6 million in 2023. This growth was attributed to:
- Software Revenues: Increased by 15% to $35.9 million from $31.3 million.
- Services Revenues: Increased by 9% to $58.9 million from $54.2 million.
| Revenue Source | 2024 (Q3) | 2023 (Q3) | Change ($) | Change (%) |
|---|---|---|---|---|
| Software | $35.9 million | $31.3 million | $4.6 million | 15% |
| Services | $58.9 million | $54.2 million | $4.7 million | 9% |
| Total Revenues | $94.8 million | $85.6 million | $9.2 million | 11% |
A Deep Dive into Certara, Inc. (CERT) Profitability
Profitability Metrics
Gross Profit Margin: For the nine months ended September 30, 2024, the gross profit margin was calculated as follows:
| Period | Revenues (in thousands) | Cost of Revenues (in thousands) | Gross Profit (in thousands) | Gross Profit Margin (%) |
|---|---|---|---|---|
| Nine Months Ended September 30, 2024 | $284,787 | $116,253 | $168,534 | 59.2 |
| Nine Months Ended September 30, 2023 | $266,327 | $106,956 | $159,371 | 59.8 |
The gross profit margin remained relatively stable, decreasing slightly from 59.8% in 2023 to 59.2% in 2024.
Operating Profit Margin: The operating profit margin for the same periods is presented below:
| Period | Operating Income (Loss) (in thousands) | Operating Profit Margin (%) |
|---|---|---|
| Nine Months Ended September 30, 2024 | $(7,734) | (2.7) |
| Nine Months Ended September 30, 2023 | $(32,307) | (12.1) |
The operating profit margin improved significantly from (12.1%) in 2023 to (2.7%) in 2024, indicating better operational efficiency despite still reporting a loss.
Net Profit Margin: The net profit margin for the periods ended September 30 is as follows:
| Period | Net Income (Loss) (in thousands) | Net Profit Margin (%) |
|---|---|---|
| Nine Months Ended September 30, 2024 | $(18,628) | (6.5) |
| Nine Months Ended September 30, 2023 | $(42,901) | (16.1) |
The net profit margin showed significant improvement, moving from (16.1%) in 2023 to (6.5%) in 2024, reflecting a substantial reduction in net losses.
Trends in Profitability Over Time: The trend analysis indicates a positive trajectory in profitability metrics. The net loss decreased by 57% from $42.9 million in 2023 to $18.6 million in 2024.
Comparison with Industry Averages: The average gross profit margin in the industry typically ranges between 60% and 70%. Thus, while the company's gross margin is slightly below the industry average, its operating and net margins show a significant recovery.
Operational Efficiency Analysis: The operational efficiency has improved with a decrease in total operating expenses from $191.7 million in 2023 to $176.3 million in 2024. Key operating expenses include:
| Expense Category | 2024 (in thousands) | 2023 (in thousands) | Change ($ in thousands)|
|---|---|---|---|
| Sales and Marketing | $34,247 | $23,351 | 10,896 |
| Research and Development | $29,333 | $26,155 | 3,178 |
| General and Administrative | $73,080 | $61,777 | 11,303 |
Despite increases in sales and marketing, R&D, and G&A expenses, the overall reduction in operating losses suggests improved cost management and operational efficiencies.
Debt vs. Equity: How Certara, Inc. (CERT) Finances Its Growth
Debt vs. Equity: How Certara, Inc. Finances Its Growth
Overview of the Company's Debt Levels
As of September 30, 2024, Certara, Inc. reported total long-term debt of $299.3 million, an increase from $294.5 million as of December 31, 2023. The current portion of long-term debt stands at $3.0 million, down from $3.02 million at year-end 2023. The company has no outstanding balances on its revolving line of credit, which has a total commitment of $100 million available through June 26, 2029.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio for Certara, Inc. as of September 30, 2024, is approximately 0.28, calculated by taking the total debt of $299.3 million and dividing it by total equity of $1.053 billion. This ratio is significantly below the industry average, which typically hovers around 0.5 to 0.7 for companies in the biotechnology sector.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
On June 26, 2024, Certara amended its Credit Agreement, increasing the principal amount of the term loan to $300 million and extending the maturity date to June 26, 2031. The interest on the term loans is pegged to the Term SOFR rate plus an applicable margin rate, which currently stands at 3.00%. The company’s term loans carry an effective interest rate of 8.96%.
How the Company Balances Between Debt Financing and Equity Funding
Certara has demonstrated a strategic approach in balancing debt and equity financing. As of September 30, 2024, the company maintained cash and cash equivalents of $233 million, which supports its liquidity needs while minimizing reliance on debt. The company also reported a net cash flow from operating activities of $31.1 million for the nine months ended September 30, 2024.
| Financial Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Total Long-term Debt | $299.3 million | $294.5 million |
| Current Portion of Long-term Debt | $3.0 million | $3.02 million |
| Debt-to-Equity Ratio | 0.28 | N/A |
| Total Equity | $1.053 billion | N/A |
| Cash and Cash Equivalents | $233 million | $234.9 million |
| Net Cash from Operating Activities | $31.1 million | $59.4 million |
Assessing Certara, Inc. (CERT) Liquidity
Assessing Liquidity and Solvency
Current and Quick Ratios
The current ratio for the company as of September 30, 2024, is 1.44, indicating that the company has 1.44 times more current assets than current liabilities. The quick ratio stands at 1.12, reflecting a solid liquidity position without relying on inventory to meet short-term obligations.
Analysis of Working Capital Trends
Working capital as of September 30, 2024, is approximately $233.0 million, slightly down from $234.9 million at the end of 2023. This indicates a stable working capital position, which is critical for maintaining operational flexibility.
Cash Flow Statements Overview
The cash flow from operating activities for the nine months ended September 30, 2024, stands at $31.1 million, a decline from $59.4 million for the same period in 2023. The breakdown of cash flows is as follows:
| Cash Flow Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash provided by operating activities | $31,097 | $59,429 |
| Net cash used in investing activities | ($15,205) | ($18,503) |
| Net cash used in financing activities | ($19,707) | ($8,195) |
| Net increase (decrease) in cash | ($1,928) | $32,624 |
Cash Flow Trends
The operating cash flow trend indicates a decrease of $28.3 million year-over-year, primarily attributed to a rise in accounts receivable and increased cash used for prepaid expenses. Investing activities have decreased slightly, while financing activities have seen a significant increase in cash outflows due to higher payments for contingent business acquisition considerations.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company maintains a cash and cash equivalents balance of $233.0 million. Additionally, it has access to a $100.0 million revolving line of credit, providing a buffer for any immediate liquidity needs. However, the increase in cash outflows from financing activities and the decline in cash provided by operating activities could pose potential liquidity concerns if trends continue.
Future capital requirements will depend on several factors, including potential acquisitions and investments, which may increase cash demands. The company believes that existing liquidity sources will be sufficient to meet operational needs for the foreseeable future.
Debt Obligations
The long-term debt outstanding as of September 30, 2024, totals $299.3 million, with scheduled maturities as follows:
| Maturity Year | Amount (in thousands) |
|---|---|
| Remainder of 2024 | $750 |
| 2025 | $3,000 |
| 2026 | $3,000 |
| 2027 | $3,000 |
| 2028 | $3,000 |
| Thereafter | $286,500 |
| Total | $299,250 |
The company is currently in compliance with its debt covenants, which is a positive indicator of its solvency.
Is Certara, Inc. (CERT) Overvalued or Undervalued?
Valuation Analysis
To evaluate the financial health of the company, we will analyze its valuation metrics, stock price trends, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The current price-to-earnings (P/E) ratio is -60.67 based on a trailing twelve months (TTM) net loss of $18.6 million for the nine months ended September 30, 2024, with a basic weighted-average common shares outstanding of 160,642,052.
Price-to-Book (P/B) Ratio
The price-to-book (P/B) ratio is calculated at 1.03 with a book value per share of approximately $6.53 as of September 30, 2024, while the current stock price is around $6.72.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value (EV) is calculated at $1.16 billion, with an EBITDA of $88.5 million for the trailing twelve months, resulting in an EV/EBITDA ratio of approximately 13.12.
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between a low of $3.75 and a high of $7.50. The current stock price is approximately $6.72, reflecting a -8.4% change year-to-date.
Dividend Yield and Payout Ratios
The company does not currently pay a dividend, resulting in a dividend yield of 0%. The payout ratio is also 0%, indicating no earnings are being distributed to shareholders.
Analyst Consensus on Stock Valuation
According to recent analyst ratings, the consensus is Hold, with 60% of analysts recommending to hold, 30% recommending to buy, and 10% recommending to sell.
| Metric | Value |
|---|---|
| P/E Ratio | -60.67 |
| P/B Ratio | 1.03 |
| EV/EBITDA Ratio | 13.12 |
| 52-Week Low | $3.75 |
| 52-Week High | $7.50 |
| Current Stock Price | $6.72 |
| Dividend Yield | 0% |
| Payout Ratio | 0% |
| Analyst Consensus | Hold |
This analysis provides a comprehensive view of the valuation metrics and current market sentiment surrounding the company, essential for potential investors to make informed decisions.
Key Risks Facing Certara, Inc. (CERT)
Key Risks Facing Certara, Inc.
The financial health of the company is subject to various internal and external risks that may impact its operations and profitability. Below are the key risk factors identified:
Industry Competition
The biopharmaceutical sector is highly competitive, with numerous players vying for market share. The company faces competition from both established firms and new entrants, which could lead to pricing pressures and reduced market share.
Regulatory Changes
Changes in regulations can significantly impact operations. The company must comply with various regulatory requirements that are subject to change, which can increase operational costs and affect service delivery.
Market Conditions
Fluctuations in market conditions, including economic downturns or changes in healthcare funding, may adversely affect demand for the company's products and services.
Operational Risks
Operational risks include potential disruptions in service delivery due to technology failures, supply chain issues, or natural disasters that can affect the company's ability to serve its clients effectively.
Financial Risks
Financial risks such as interest rate fluctuations, currency exchange rate variability, and liquidity constraints can affect the company’s financial performance. The company's effective income tax rate was reported at 17% for the three months ended September 30, 2024.
Strategic Risks
Strategic risks include the potential failure to execute business strategies effectively, including mergers and acquisitions, which can lead to integration challenges and additional costs. The company completed an acquisition of Chemaxon for $90 million on October 1, 2024.
Recent Earnings Reports Insights
According to the latest earnings report, the company reported a net loss of $1.4 million for the three months ended September 30, 2024, a significant improvement compared to a net loss of $49.0 million for the same period in 2023. This change is attributed to a $47.4 million decrease in operating expenses, primarily due to the absence of goodwill impairment charges recorded in the previous year.
Mitigation Strategies
The company has implemented various strategies to mitigate risks, including maintaining adequate cash reserves and diversifying its product offerings. As of September 30, 2024, the company reported $233 million in cash and cash equivalents.
| Key Metrics | 2024 | 2023 |
|---|---|---|
| Net Loss | $1,371,000 | $48,965,000 |
| Total Revenues | $284,787,000 | $266,327,000 |
| Operating Expenses | $176,268,000 | $191,678,000 |
| Cash and Cash Equivalents | $233,023,000 | $234,951,000 |
| Effective Income Tax Rate | 17% | 9% |
Future Growth Prospects for Certara, Inc. (CERT)
Future Growth Prospects for Certara, Inc. (CERT)
Analysis of Key Growth Drivers
Certara, Inc. has identified several key growth drivers that are poised to enhance its market position and revenue streams.
- Product Innovations: The company has reported a significant increase in software revenues, which rose by 16% to $113.4 million for the nine months ended September 30, 2024, compared to the same period in 2023.
- Market Expansions: The total revenues increased by 7%, amounting to $284.8 million for the nine months ended September 30, 2024.
- Acquisitions: The recent acquisition of Chemaxon for $90 million is expected to enhance Certara's capabilities in scientific informatics.
Future Revenue Growth Projections and Earnings Estimates
Analysts project that Certara's revenue growth will continue at a steady pace, with expectations for total revenues to reach approximately $400 million by the end of 2025. This projection is supported by strong demand for their technology-enabled services and ongoing client expansions.
Strategic Initiatives or Partnerships that May Drive Future Growth
The company's strategic initiatives include:
- Investment in AI Technologies: Certara is focusing on integrating AI across its product portfolio, which is expected to enhance operational efficiencies and product offerings.
- Expansion of Client Base: The company has successfully increased its client base, which contributes to recurring revenue growth from existing customers.
Competitive Advantages that Position the Company for Growth
Certara's competitive advantages include:
- Strong Brand Reputation: The company is recognized as a leading provider of biosimulation technology, which positions it favorably in the biopharmaceutical market.
- Diverse Product Portfolio: The combination of software and technology-enabled services allows Certara to offer comprehensive solutions to its clients.
Financial Overview
The following table summarizes Certara's financial performance for the nine months ended September 30, 2024:
| Financial Metric | 2024 | 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Revenues | $284.8 million | $266.3 million | $18.5 million | 7% |
| Software Revenues | $113.4 million | $98.1 million | $15.4 million | 16% |
| Services Revenues | $171.4 million | $168.3 million | $3.1 million | 2% |
| Net Loss | $(18.6) million | $(42.9) million | $24.3 million | 57% |
Certara's growth strategy focuses on leveraging its technological advancements and expanding its market reach, positioning itself for sustained growth in the evolving biopharmaceutical landscape.
Certara, Inc. (CERT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Certara, Inc. (CERT) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Certara, Inc. (CERT)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Certara, Inc. (CERT)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.